MK-8745Aurora A inhibitor,potent and selective CAS# 885325-71-3 |
- MLN8237 (Alisertib)
Catalog No.:BCC2166
CAS No.:1028486-01-2
- SCH-1473759
Catalog No.:BCC1934
CAS No.:1094069-99-4
- Reversine
Catalog No.:BCC1892
CAS No.:656820-32-5
- AZD1152
Catalog No.:BCC1393
CAS No.:722543-31-9
- XL228
Catalog No.:BCC2058
CAS No.:898280-07-4
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 885325-71-3 | SDF | Download SDF |
| PubChem ID | 11676373 | Appearance | Powder |
| Formula | C20H19ClFN5OS | M.Wt | 431.91 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (231.53 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (3-chloro-2-fluorophenyl)-[4-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]piperazin-1-yl]methanone | ||
| SMILES | C1CN(CCN1CC2=NC(=CC=C2)NC3=NC=CS3)C(=O)C4=C(C(=CC=C4)Cl)F | ||
| Standard InChIKey | YCRFPWKUUNKNDN-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C20H19ClFN5OS/c21-16-5-2-4-15(18(16)22)19(28)27-10-8-26(9-11-27)13-14-3-1-6-17(24-14)25-20-23-7-12-29-20/h1-7,12H,8-11,13H2,(H,23,24,25) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | MK-8745 is a potent and selective inhibitor of Aurora A with an IC50 value of 0.6 nM. | |||||
| Targets | Aurora A | |||||
| IC50 | 0.6 nM | |||||
MK-8745 Dilution Calculator
MK-8745 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3153 mL | 11.5765 mL | 23.153 mL | 46.3059 mL | 57.8824 mL |
| 5 mM | 0.4631 mL | 2.3153 mL | 4.6306 mL | 9.2612 mL | 11.5765 mL |
| 10 mM | 0.2315 mL | 1.1576 mL | 2.3153 mL | 4.6306 mL | 5.7882 mL |
| 50 mM | 0.0463 mL | 0.2315 mL | 0.4631 mL | 0.9261 mL | 1.1576 mL |
| 100 mM | 0.0232 mL | 0.1158 mL | 0.2315 mL | 0.4631 mL | 0.5788 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
MK-8745 is a novel and selective inhibitor of Aurora A with IC50 value of 0.6 nM [1].
Aurora A kinase is a member of mitotic serine/threonine kinases and plays an important role in cellular division by controlling chromatid segregation. It has been reported that abnormal expression of Aurora A is correlated with the high occurrence of cancer and its expression determines cell sensitivity to MK-8745 treatment [1].
MK-8745 is a potent Aurora A inhibitor. When tested with p53-/+ cell lines, MK-8745 treatment induced apoptotic cell death in a p53-dependent manner through inhibiting Aurora A activity [1]. In non-Hodgkin lymphoma (NHL) cell lines, MK-8745 treatment arrested cell cycle in G2/M phase and induced cell death via inhibiting Aurora A kinase [2]. In HCT 116 Puma (-), HCT116 p21 (-), HCT116 Bax(-) and HCT116 Chk2(-) cell lines, MK-8745 treatment induced cell apoptosis with the percent of 25%, 22%, 25%, and 22%, respectively [3].
In female athymic nude mice model subcutaneous xenografted with HCT116 Puma (-), HCT116 p21 (-), HCT116 Bax(-) and HCT116 Chk2(-) cells, administration of MK-8745 significantly inhibited tumor growth [3].
References:
[1]. Nair, J.S., A.L. Ho, and G.K. Schwartz, The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent. Cell Cycle, 2012. 11(4): p. 807-17.
[2]. Chowdhury, A., S. Chowdhury, and M.Y. Tsai, A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines. Leuk Lymphoma, 2012. 53(3): p. 462-71.
[3]. Shionome, Y., et al., Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors. PLoS One, 2013. 8(1): p. e55457.
- Kongensin A
Catalog No.:BCN4432
CAS No.:885315-96-8
- W-13 hydrochloride
Catalog No.:BCC6620
CAS No.:88519-57-7
- Rosamultin
Catalog No.:BCN7391
CAS No.:88515-58-6
- LY 2389575 hydrochloride
Catalog No.:BCC7985
CAS No.:885104-09-6
- GW9508
Catalog No.:BCC1102
CAS No.:885101-89-3
- Dichotomitin
Catalog No.:BCN8524
CAS No.:88509-91-5
- ARRY 520 trifluoroacetate
Catalog No.:BCC2391
CAS No.:885060-09-3
- ARRY-520 R enantiomer
Catalog No.:BCC1368
CAS No.:885060-08-2
- Benzotetramisole
Catalog No.:BCC8861
CAS No.:885051-07-0
- Farrerol 7-O-glucoside
Catalog No.:BCN6412
CAS No.:885044-12-2
- Manassantin A
Catalog No.:BCC8207
CAS No.:88497-87-4
- Artesunate
Catalog No.:BCN2457
CAS No.:88495-63-0
- HJC 0350
Catalog No.:BCC6302
CAS No.:885434-70-8
- Minumicrolin
Catalog No.:BCN4433
CAS No.:88546-96-7
- CCT128930
Catalog No.:BCC3904
CAS No.:885499-61-6
- 5'-O-Acetyljuglanin
Catalog No.:BCN6846
CAS No.:885697-82-5
- c-FMS inhibitor
Catalog No.:BCC1472
CAS No.:885704-21-2
- Fmoc-ε-Acp-OH
Catalog No.:BCC3206
CAS No.:88574-06-5
- Isomexoticin
Catalog No.:BCN4434
CAS No.:88585-86-8
- LY2119620
Catalog No.:BCC5564
CAS No.:886047-22-9
- Chrysin 7-O-beta-gentiobioside
Catalog No.:BCN2943
CAS No.:88640-89-5
- Cerebroside B
Catalog No.:BCN4435
CAS No.:88642-46-0
- Apogossypolone (ApoG2)
Catalog No.:BCC2237
CAS No.:886578-07-0
- 11-Hydroxy-sugiol
Catalog No.:BCN2510
CAS No.:88664-08-8
A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.[Pubmed:21879811]
Leuk Lymphoma. 2012 Mar;53(3):462-71.
Selective small-molecule kinase inhibitors have encouraging clinical efficacy in several malignancies. These agents are still limited to a subset of patients, indicating the need to develop therapeutic biomarkers that influence clinical benefit. In this study, we demonstrate that treatment with MK-8745, a novel Aurora-A specific inhibitor, leads to cell cycle arrest at the G2/M phase with accumulation of tetraploid nuclei followed by cell death in non-Hodgkin lymphoma (NHL) cell lines. The sensitivity of the cell lines to MK-8745 is correlated with the expression level of Aurora-A activator. The siRNA knockdown of Aurora-A activator TPX2 (targeting protein for Xenopus kinase-like protein 2) increased MK-8745 sensitivity in less-MK-8745-sensitive NHL cell lines, whereas overexpression of TPX2 in high-MK-8745-sensitive NHL cell lines increased drug resistance. Our results indicate that TPX2 may serve as a biomarker for identifying subpopulations of patients sensitive to Aurora-A inhibitor treatment.
